



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: DVAX

| | |
|---------------|----------------------------|
| Last Trade: | 5.60 |
| Trade Time: | 4:00 PM ET May 23, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 3.20 - 17.50 |
| Volume | N/A |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 19, 2017*
[Dynavax to Present Data on SD-101 in Combination with KEYTRUDA\(R\) at the 2017 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- May 8, 2017*
[Dynavax Reports First Quarter 2017 Financial Results](#)
- Apr 3, 2017*
[Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B](#)
- Mar 20, 2017*
[Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting](#)
- Mar 13, 2017*
[Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 13, 2017*
[Annual Report \(10-K\)](#)
- Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*
[Quarterly Report \(10-Q\)](#)